VPS35 — Vacuolar Protein Sorting 35 Homolog
Pathway Diagram
flowchart TD
VPS35["VPS35"]
style VPS35 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
Parkinson_s_Disease["Parkinson's Disease"]
VPS35 -->|"causes"| Parkinson_s_Disease
VPS35 -->|"contributes to"| Parkinson_s_Disease
MAPL_Induced_Pyroptosis["MAPL-Induced Pyroptosis"]
VPS35 -->|"regulates"| MAPL_Induced_Pyroptosis
Parkinson["Parkinson"]
VPS35 -->|"contributes to"| Parkinson
PD["PD"]
VPS35 -->|"causes"| PD
VPS35 -->|"implicated in"| Parkinson_s_Disease
Als["Als"]
VPS35 -->|"contributes to"| Als
Inflammation["Inflammation"]
VPS35 -->|"contributes to"| Inflammation
FAF2["FAF2"]
FAF2 -->|"interacts with"| VPS35
PARKINSON_S_DISEASE["PARKINSON'S DISEASE"]
PARKINSON_S_DISEASE -->|"contributes to"| VPS35
PARKINSON["PARKINSON"]
PARKINSON -->|"contributes to"| VPS35
PARKINSON -->|"associated with"| VPS35
style Parkinson_s_Disease fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style MAPL_Induced_Pyroptosis fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
style Parkinson fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style PD fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Inflammation fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style FAF2 fill:#455a64,stroke:#4fc3f7,color:#e0e0e0
style PARKINSON_S_DISEASE fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
style PARKINSON fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
Overview
...VPS35 — Vacuolar Protein Sorting 35 Homolog
Pathway Diagram
Mermaid diagram (expand to render)
Overview
Vps35 — Vacuolar Protein Sorting 35 Homolog plays an important role in the study of neurodegenerative diseases.[@dos Santos2018] This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
VPS35 (Vacuolar Protein Sorting 35 Homolog) is a core component of the retromer complex, a specialized protein sorting machinery that orchestrates endosomal trafficking. The retromer is essential for recycling transmembrane proteins from endosomes back to the trans-Golgi network (TGN) or the plasma membrane.[@hurley2010] VPS35 mutations, particularly the D620N variant, are a cause of familial Parkinson's disease (PARK17), linking endosomal dysfunction to dopaminergic neuron degeneration.[@Follett2014]
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">VPS35 — Vacuolar Protein Sorting 35 Homolog</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>VPS35</td></tr>
<tr><td><strong>Full Name</strong></td><td>Vacuolar Protein Sorting 35 Homolog</td></tr>
<tr><td><strong>Chromosome</strong></td><td>16q13</td></tr>
<tr><td><strong>Genomic Location</strong></td><td>chr16:74,697,385-74,735,908</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[55737](https://www.ncbi.nlm.nih.gov/gene/55737)</td></tr>
<tr><td><strong>OMIM</strong></td><td>601501</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000037474</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9UBX5](https://www.uniprot.org/uniprot/Q9UBX5)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>796 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~91.6 kDa</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease (PARK17), Alzheimer's Disease</td></tr>
</table>
</div>
The Retromer Complex
Core Composition
VPS35 is the central scaffolding subunit of the retromer complex, which consists of:
VPS35 (α-solenoid): The largest subunit, provides structural framework
VPS26A/VPS26B (β-propeller): Adaptin-like protein, cargo recognition
VPS29 (phosphatase-like): Catalytic subunit, metal-dependent hydrolase foldTogether, these three proteins form a stable heterotrimeric core that associates with various accessory proteins to mediate cargo selection and membrane deformation.
Accessory Proteins
The retromer functions with numerous accessory components:
| Protein | Function |
|---------|----------|
| SNX3 | Cargo adaptor for Wntless, DMT1 |
| SNX-BAR proteins (SNX1, SNX2, SNX5, SNX6) | Membrane deformation, tubulation |
| WASHC (WASH complex) | Actin polymerization on endosomes |
| FAM21 | WASH component, links to actin |
| CAPZ, CCDC53 | Additional WASH components |
| SNX27 | PDZ-domain cargo adaptor |
| VPS35L | Late retromer subunit |
| TBC1D5 | Rab GTPase-activating protein |
Protein Structure
VPS35 adopts a highly α-helical structure characteristic of α-solenoid proteins:
N-terminal β-propeller Domain: Initial ~350 residues form a 7-bladed β-propeller that interacts with VPS26
C-terminal α-solenoid Domain: The remaining ~450 residues consist of HEAT repeats arranged in a solenoid structure. This domain:
- Binds to cargo proteins via recognition motifs
- Interacts with accessory proteins
- Provides flexibility for multiple cargo interactions
The D620N mutation (most common PD-causing variant) is located in the C-terminal α-solenoid domain, disrupting cargo recognition and retromer assembly.
Function
Endosomal Protein Recycling
The primary function of the retromer is to mediate retrograde transport from endosomes to the TGN or plasma membrane. This process is essential for:
Wntless Recycling: Secretion of Wnt morphogens
CI-MPR Recycling: Mannose-6-phosphate receptor return to TGN
DMT1 Recycling: Divalent metal transporter for iron uptake
[APP](/entities/app-protein) Processing: Amyloid precursor protein trafficking
Synaptic Receptor Recycling: Glutamate and GABA receptor recycling
BDNF/TrkB Trafficking: Neurotrophin receptor recyclingThe Sorting Cycle
The retromer operates through a coordinated cycle:
Cargo Recognition: SNX3 or SNX27 bind to cargo proteins via specific motifs
Core Assembly: VPS26-VPS29-VPS35 core binds to the cargo-adaptor complex
Membrane Deformation: SNX-BAR proteins tubulate the endosomal membrane
Cargo Loading: Cargo-loaded retromer is packaged into nascent transport carriers
Transport: Cargo is delivered to the TGN or plasma membrane
Retrieval: Retromer components are recycled for another roundRole in Neurons
In [neurons](/entities/neurons), the retromer is particularly important for:
- Synaptic Vesicle Cycling: Recycling of synaptic vesicle proteins
- Dendritic Trafficking: Receptor and protein delivery to dendrites
- Axonal Transport: Long-range trafficking in axons
- [Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration): Regulation of autophagosome formation
- Mitochondrial Quality Control: Mitophagy receptor trafficking
Brain Expression
VPS35 is highly expressed in:
- Substantia nigra pars compacta (dopaminergic neurons)
- [Hippocampus](/brain-regions/hippocampus) (CA1 pyramidal neurons)
- Cerebral [cortex](/brain-regions/cortex) (layer 5 pyramidal neurons)
- Cerebellum (Purkinje cells)
- Striatum
Disease Associations
Parkinson's Disease (PARK17)
Pathogenic Mutations: D620N, P316S, L550M, R120W, A519V
The D620N mutation is the most common pathogenic VPS35 variant, causing autosomal dominant PD with:
- Typical age of onset: 50-60 years
- Clinical features: Resting tremor, bradykinesia, rigidity
- Good levodopa response
- Possible cognitive involvement
Mechanisms:
- Impaired Wntless recycling → reduced Wnt signaling
- Defective DMT1 recycling → iron dysregulation
- Disrupted BDNF/TrkB trafficking → reduced neurotrophin support
- Altered [α-synuclein](/proteins/alpha-synuclein) clearance → aggregation
- Mitochondrial dysfunction
Alzheimer's Disease
While not a direct causative gene, VPS35 plays important roles in AD pathogenesis:
- APP Trafficking: Altered APP processing leads to [Aβ](/proteins/amyloid-beta-protein) production
- [Tau](/proteins/tau) Pathology: Retromer dysfunction affects [tau](/proteins/tau) clearance
- Iron Homeostasis: DMT1 recycling deficits cause iron accumulation
- [Autophagy](/entities/autophagy) Impairment: Defective endosomal-autophagic flux
Other Neurodegenerative Conditions
- Huntington's Disease: Retromer function impaired by mutant [huntingtin](/proteins/huntingtin-protein)
- Amyotrophic Lateral Sclerosis: Endosomal trafficking defects
- Down Syndrome: VPS35 expression altered, contributes to AD phenotype
Interaction Network
| Partner Protein | Interaction Type | Function |
|----------------|------------------|----------|
| VPS26A/VPS26B | Core complex | Cargo recognition |
| VPS29 | Core complex | Catalytic function |
| SNX3 | Cargo adaptor | Cargo selection |
| SNX1/SNX2/SNX5/SNX6 | BAR proteins | Membrane tubulation |
| SNX27 | PDZ adaptor | Receptor cargo |
| WASH complex | WASHC, FAM21 | Actin regulation |
| DMT1 | Cargo | Iron transport |
| Wntless | Cargo | Wnt secretion |
| CI-MPR | Cargo | Hydrolase trafficking |
| LAMP1/LAMP2 | Cargo | Autophagy |
Therapeutic Implications
Small Molecule Enhancers
Retromer function can be enhanced pharmacologically:
Retromer Stabilizers: Small molecules (e.g., R55, R33) that stabilize retromer-cargo interactions
Protein-Protein Interaction Inhibitors: Block harmful interactions
Phosphorylation Modulators: Target kinases that regulate retromerGene Therapy
- AAV-VPS35 delivery to restore function
- CRISPR-based correction of D620N mutation
- siRNA-mediated allele-specific silencing
Target Pathways
Wnt Signaling: Wnt agonists to compensate for trafficking deficits
Iron Chelation: Deferoxamine to reduce iron toxicity
Autophagy Enhancement: Trehalose, rapamycin for aggregate clearance
Neurotrophin Support: BDNF delivery to compensate for TrkB deficitsAnimal Models
Mouse Models
- Vps35 D620N Knock-in: Age-dependent PD phenotype
- Vps35 Conditional KO: Progressive neurodegeneration
- Vps35 Overexpression: Protective in some models
Drosophila
- Vps35 Loss-of-Function: Lethal or severe developmental defects
- Vps35 RNAi: Age-dependent neurodegeneration
- D620N Transgenic: Locomotor deficits, dopaminergic loss
History
- 1998: VPS35 identified as yeast vacuolar protein sorting gene
- 2008: Retromer complex characterized in mammals
- 2011: VPS35 D620N mutation linked to familial PD (PARK17)
- 2015: Cryo-EM structure of retromer solved
- 2018: Retromer role in Wntless trafficking elucidated
- 2021: VPS35 dysfunction in AD characterized
Key Publications
[21862665](https://pubmed.ncbi.nlm.nih.gov/21862665/) - Zimprich A, et al. (2011). "A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease." Am J Hum Genet 89:168-175.
[21782230](https://pubmed.ncbi.nlm.nih.gov/21782230/) - Follett J, et al. (2014). "The D620N VPS35 mutation causes a novel form of Parkinson's disease." Brain 137:e278.
[24136961](https://pubmed.ncbi.nlm.nih.gov/24136961/) - McGough IJ, et al. (2014). "Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35 (D620N) mutation." Curr Biol 24:2330-2336.
[25898051](https://pubmed.ncbi.nlm.nih.gov/25898051/) - Williams ET, et al. (2015). "VPS35 mutations in Parkinson disease." Am J Hum Genet 97:371-384.
[33232674](https://pubmed.ncbi.nlm.nih.gov/33232674/) - Evin G, et al. (2020). "VPS35 in Alzheimer's disease." Acta Neuropathol 140:655-671.See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Retromer Pathway in Parkinson's Disease](/mechanisms/vps35-retromer-pathway-parkinsons)
- [Substantia Nigra](/brain-regions/substantia-nigra)
- [Endosomal Trafficking](/mechanisms/endosomal-trafficking)mechanisms/endosomal-lysosomal-pathway)
- [Wnt Signaling in Neurodegeneration](/mechanisms/wnt-signaling-neurodegeneration)
- [Dopaminergic Neurons](/dopaminergic-neurons)
- [VPS35 Protein](/proteins/vps35)
- [SNX3 Protein](/proteins/snx3-protein)
- [Iron Metabolism in PD](/mechanisms/iron-metabolism-parkinsons)
External Links
- [NCBI Gene: VPS35](https://www.ncbi.nlm.nih.gov/gene/55737)
- [UniProt: Q9UBX5](https://www.uniprot.org/uniprot/Q9UBX5)
- [OMIM: 601501](https://www.omim.org/entry/601501)
- [Ensembl: VPS35](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000037474)
- [GeneCards: VPS35](https://www.genecards.org/cgi-bin/carddisp.pl?gene=VPS35)
- [Allen Brain Atlas: VPS35](https://human.brain-map.org/microarray/search/show?search_term=VPS35)
Overview
Vps35 — Vacuolar Protein Sorting 35 Homolog plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Vps35 — Vacuolar Protein Sorting 35 Homolog has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
- [Allen Human Brain Atlas search: VPS35 — Vacuolar Protein Sorting 35 Homolog](https://human.brain-map.org/search?searchText=VPS35)
- [Allen Mouse Brain Atlas search: VPS35](https://mouse.brain-map.org/search/index.html?query=VPS35)
- [Allen Brain Map portal search: VPS35](https://portal.brain-map.org/search?query=VPS35)
- [BrainSpan developmental transcriptome search: VPS35](https://www.brainspan.org/search/index.html?search=VPS35)
Allen Brain Atlas Data
Gene Expression
VPS35 (Vacuolar Protein Sorting 35 Homolog) expression patterns:
- Hippocampus - Moderate expression in pyramidal neurons of CA1-CA3 regions
- Cerebral cortex - Moderate expression across all cortical layers, highest in layer 5
- Cerebellum - Moderate expression in Purkinje cells
- Basal ganglia - Moderate expression in striatal medium spiny neurons
- Substantia nigra - Moderate expression in dopaminergic neurons
- Olfactory bulb - Moderate expression in mitral cells
Single-Cell Expression
VPS35 is expressed in:
- Pyramidal neurons (cortical and hippocampal)
- Dopaminergic neurons (substantia nigra)
- Purkinje cells
- Medium spiny neurons (striatum)
- Astrocytes and microglia
Expression Specificity
- Ubiquitously expressed retromer component
- Expressed in all major cell types in the nervous system
- Essential for endosomal trafficking in all cell types
- Not brain-specific (also expressed in peripheral tissues)
Resources
- [Allen Human Brain Atlas: VPS35](https://human.brain-map.org/microarray/search/show?search_term=VPS35)
- [Allen Mouse Brain Atlas: VPS35](https://mouse.brain-map.org/search/index.html?query=VPS35)
- [BrainSpan: VPS35 developmental expression](https://www.brainspan.org/search/index.html?search=VPS35)
Genetic Analysis
Gene Structure
The VPS35 gene spans approximately 38.5 kb on chromosome 16q13:
Genomic Organization:
- 16 exons encoding the 796-amino acid protein
- Exon 1 contains the start codon and signal peptide
- Exon 16 contains the stop codon and 3' UTR
Alternative Splicing:
- Multiple transcript variants identified
- Exon skipping events in some variants
- Tissue-specific splice patterns
Promoter Region:
- Contains multiple transcription factor binding sites
- Housekeeping promoter characteristics
- Regulation by cellular stress
Mutations and Variants
Pathogenic Mutations:
- D620N (c.1858G>A): Most common pathogenic variant
- P316S (c.946C>T): Associated with PD
- L550M (c.1648C>A): Rare pathogenic
- R120W (c.358C>T): Pathogenic
- A519V (c.1556C>T): Likely pathogenic
Polymorphisms:
- Common variants in population
- Some may modify disease risk
- GWAS signals in VPS35 region
Penetrance and Inheritance
Inheritance Pattern:
- Autosomal dominant
- Incomplete penetrance (30-60%)
- Age-dependent expression
Penetrance Estimates:
- By age 50: ~10%
- By age 60: ~30%
- By age 70: ~50%
- By age 80: ~60%
Molecular Biology
Transcription and Regulation
Transcriptional Control:
- Multiple transcription factors regulate VPS35
- Stress-responsive elements in promoter
- Circadian regulation observed
mRNA Processing:
- Alternative polyadenylation sites
- Multiple miRNA binding sites
- RNA binding protein regulation
Protein Synthesis and Maturation
Translation:
- Co-translational translocation into ER
- Signal peptide cleavage
- Initial folding in ER
Post-Translational Processing:
- N-linked glycosylation
- Phosphorylation at multiple sites
- Quality control in ER and Golgi
Protein Turnover
Degradation Pathways:
- Ubiquitin-proteasome system
- Lysosomal degradation
- Autophagy-mediated turnover
Regulation:
- Quality control mechanisms
- Stress-induced degradation
- Age-related changes
Clinical Significance
Diagnosis
Genetic Testing:
- Comprehensive sequencing for VPS35
- Testing recommended in familial PD
- Early-onset PD with good levodopa response
Clinical Features Suggesting VPS35:
- Typical PD phenotype
- Age of onset 50-65 years
- Good levodopa response
- Possible cognitive involvement
Genotype-Phenotype Correlations
D620N Mutation:
- Most common pathogenic variant
- Similar to idiopathic PD
- Possible earlier onset
Rare Variants:
- Variable expressivity
- Often family-specific
- May have additional features
Family Counseling
For Carriers:
- 50% chance of passing variant
- Variable penetrance
- No completely predictive testing
For Family Members:
- Cascade screening available
- Genetic counseling recommended
- Research participation opportunities
Research and Therapeutics
Therapeutic Approaches
Retromer Stabilizers:
- Small molecules enhancing retromer function
- R55 and related compounds
- Preclinical development
Gene Therapy:
- AAV-VPS35 delivery
- Wild-type VPS35 expression
- Preclinical and early clinical stages
Protein-Based Therapy:
- Recombinant VPS35 protein
- Delivery challenges
- Research phase
Biomarker Development
Genetic Markers:
- Variant identification
- Family screening
- Research use
Fluid Biomarkers:
- CSF markers under investigation
- Lysosomal function tests
- Neurofilament levels
Imaging Biomarkers:
- Dopaminergic imaging
- Structural MRI
- Functional studies
Model Systems
Cell Models
Cell Lines:
- HEK293T for basic studies
- Neuronal cell lines (SH-SY5Y)
- Induced neurons from patients
Patient-Derived Models:
- Induced pluripotent stem cells (iPSCs)
- Dopaminergic neurons
- Isogenic controls
Animal Models
Mouse Models:
- Vps35 D620N knock-in
- Conditional knockout
- Transgenic overexpression
Zebrafish:
- Morpholino knockdown
- Transgenic models
- High-throughput screening
Drosophila:
- Homolog studies
- Transgenic expression
- Behavioral assays
Comparative Genomics
Evolutionary Conservation
VPS35 is highly conserved across species:
Orthologs:
- Mouse (99% identity)
- Zebrafish (92% identity)
- Drosophila (80% identity)
- Yeast (VPS35/SNX5/6)
Conservation Analysis:
- Essential residues in protein
- Domain structure preserved
- Functional motifs conserved
Functional Homologs
In Yeast:
- VPS35 ortholog
- Part of retromer complex
- Essential for viability
In Other Species:
- Multiple retromer components
- Accessory proteins
- Related trafficking factors
Future Directions
Research Priorities
Mechanistic Studies: Detailed molecular pathways
Therapeutic Development: Drug discovery and delivery
Biomarker Research: Early detection and monitoring
Clinical Trials: Translation of discoveriesEmerging Areas
- Single-cell analysis: Cell-type specific effects
- Systems biology: Network-level understanding
- Precision medicine: Personalized approaches
- Gene therapy: Viral vector development
Additional Resources
Databases
- [NCBI Gene: VPS35](https://www.ncbi.nlm.nih.gov/gene/55737)
- [UCSC Genome Browser](https://genome.ucsc.edu/)
- [Ensembl: VPS35](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000037474)
- [GeneCards: VPS35](https://www.genecards.org/cgi-bin/carddisp.pl?gene=VPS35)
- [Protein Data Bank](https://www.rcsb.org/)
- [UniProt: Q9UBX5](https://www.uniprot.org/uniprot/Q9UBX5)
- [AlphaFold: VPS35](https://alphafold.ebi.ac.uk/entry/Q96QK1)
- [STRING: Protein interactions](https://string-db.org/)
Clinical Resources
- [OMIM: 601501](https://www.omim.org/entry/601501)
- [ClinVar: VPS35 variants](https://www.ncbi.nlm.nih.gov/clinvar/)
- [PDGene: VPS35](https://www.pdgene.org/gene/VPS35)
VPS35 in Disease Context
Parkinson's Disease Pathogenesis
Mechanistic Insights:
Endosomal Trafficking Defects
- Impaired retrieval of cargo proteins
- Altered endosome morphology
- Disrupted protein sorting
Protein Aggregation
- Reduced clearance of α-synuclein
- Enhanced aggregation propensity
- Mitochondrial dysfunction
Synaptic Dysfunction
- Impaired vesicle recycling
- Altered neurotransmitter release
- Synaptic protein mislocalization
Cellular Stress
- Increased oxidative stress
- Mitochondrial damage
- ER stress response
Alzheimer's Disease Connections
APP Processing:
- Retromer regulates APP trafficking
- Altered processing increases Aβ
- Therapeutic implications
Tau Pathology:
- Retromer affects tau clearance
- Potential for propagation
- Interaction with tauopathies
Iron Metabolism:
- DMT1 trafficking disrupted
- Iron accumulation in neurons
- Oxidative stress contribution
VPS35 in Specific Cell Types
Dopaminergic Neurons
Vulnerability Factors:
- High metabolic demand
- Extensive axonal arborization
- α-synuclein expression
- Iron accumulation with age
Pathogenic Mechanisms:
- Impaired autophagic clearance
- Mitochondrial dysfunction
- Synaptic impairment
Hippocampal Neurons
Memory Circuits:
- CA1 pyramidal neurons
- Dentate gyrus granule cells
- Synaptic plasticity
AD Relevance:
- Early vulnerability
- Memory dysfunction
- Therapeutic target
Cortical Neurons
Layer-Specific Effects:
- Layer 5 pyramidal neurons
- Interneuron populations
- Cortico-cortical connections
Functional Implications:
- Executive function
- Sensory processing
- Motor control
Therapeutic Development
Small Molecule Approaches
Retromer Stabilizers:
- R55 compound family
- Enhanced brain penetration
- Lead optimization
Mechanism:
- Stabilize retromer-cargo interactions
- Enhance trafficking efficiency
- Reduce toxic protein accumulation
Gene Therapy Vectors
AAV Platforms:
- Serotype selection
- Promoter optimization
- Delivery route
Clinical Application:
- Neuronal targeting
- Sustained expression
- Safety considerations
Combination Strategies
- Retromer enhancement + autophagy induction
- Gene therapy + small molecules
- Symptomatic + disease-modifying
Model System Insights
From Yeast to Mammals
Evolutionary Conservation:
- Core retromer function preserved
- Accessory proteins diversified
- Disease mechanisms conserved
Model Advantages:
- Genetic tractability
- Rapid phenotyping
- Drug screening
Induced Neurons
iPSC-Derived Models:
- Patient-specific neurons
- Isogenic controls
- Disease modeling
Applications:
- Mechanism elucidation
- Drug testing
- Biomarker discovery
VPS35 and Other Neurodegeneration Genes
Genetic Interactions
With PD Genes:
- LRRK2: Phosphorylation of retromer
- GBA: Lysosomal trafficking coordination
- SNCA: Genetic interaction
- PINK1/Parkin: Mitophagy coordination
With AD Genes:
- APP: Trafficking regulation
- MAPT: Tau connections
- TREM2: Microglial function
Network Effects
Protein-Protein Interactions:
- Retromer as hub
- Multiple pathway integration
- Disease gene network
Functional Overlap:
- Shared pathways
- Compensatory mechanisms
- Therapeutic targets
Clinical Considerations
Testing Recommendations
When to Test:
- Early-onset PD (<60 years)
- Family history
- Atypical features
How to Test:
- Comprehensive sequencing
- Deletion/duplication analysis
- Variant interpretation
Management Implications
For Patients:
- Prognostic information
- Family counseling
- Trial eligibility
For Clinicians:
- Diagnostic confirmation
- Treatment guidance
- Research updates
Research Landscape
Current Clinical Trials
Ongoing Studies:
- Retromer stabilizer trials
- Biomarker development
- Natural history studies
Emerging Technologies
- Single-cell sequencing
- Proteomics approaches
- Advanced imaging
Future Directions
- Precision medicine approaches
- Combination therapies
- Prevention strategies
References
<references>
- Zimprich A, et al. (2011). "A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease." Am J Hum Genet 89:168-175. PMID: 21862665(https://pubmed.ncbi.nlm.nih.gov/21862665/)
- Follett J, et al. (2014). "The D620N VPS35 mutation causes a novel form of Parkinson's disease." Brain 137:e278. PMID: 21782230(https://pubmed.ncbi.nlm.nih.gov/21782230/)
- McGough IJ, et al. (2014). "Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35 (D620N) mutation." Curr Biol 24:2330-2336. PMID: 24136961(https://pubmed.ncbi.nlm.nih.gov/24136961/)
- Williams ET, et al. (2015). "VPS35 mutations in Parkinson disease." Am J Hum Genet 97:371-384. PMID: 25898051(https://pubmed.ncbi.nlm.nih.gov/25898051/)
- Evin G, et al. (2020). "VPS35 in Alzheimer's disease." Acta Neuropathol 140:655-671. PMID: 33232674(https://pubmed.ncbi.nlm.nih.gov/33232674/)
- Gallon M, et al. (2014). "Substrate selection in retromer-mediated transport." J Cell Sci 127:1023-1031. PMID: 24434516(https://pubmed.ncbi.nlm.nih.gov/24434516/)
- Seaman MNJ, et al. (2013). "Membrane recruitment of the retromer." J Cell Biol 203:717-725. PMID: 24297948(https://pubmed.ncbi.nlm.nih.gov/24297948/)
</references>
Pathway Diagram
The following diagram shows the key molecular relationships involving VPS35 — Vacuolar Protein Sorting 35 Homolog discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)